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CpG islands are associated with at least half of all cellular genes and are normally methylation-free. Dense methylation of
cytosine residues within islands causes strong and heritable transcriptional silencing. Such silencing normally occurs almost
solely at genes subject to genomic imprinting or to X chromosome inactivation. Aberrant methylation of CpG islands associ-
ated with tumor suppressor genes has been proposed to contribute to carcinogenesis. However, questions of mechanisms
underlying the cancer changes and the precise consequences for tumorigenesis exist in the field, and must continue to be
addressed before the importance of abnormalities in genomic methylation patterns in carcinogenesis can be fully under-
stood. In this article, two workers in DNA methylation, one concentrating on cancer biology and the other on developmental
biology, address recurrent questions about cancer epigenetics from different perspectives.The goal is to highlight important
controversies in the field which can be productive targets of ongoing and future research.
The past several years have seen a surge of interest in the area
of epigenetics in general, and in particular the position of this
mode of heritable gene expression states in cancer. Our under-
standing of chromatin with respect to the components that
specify for states of gene expression is growing rapidly, and this
body of knowledge is establishing a base from which to under-
stand abnormal as well as normal gene expression events. In
this regard, an especially active field in cancer research is con-
cerned with patterns of aberrant gene promoter hypermethyla-
tion that have been associated with loss of transcription of a
growing list of genes in virtually every type of human cancer
(Jones and Laird, 1999; Baylin and Herman, 2000). Much evi-
dence has accrued, particularly for classic tumor suppressor
genes, to solidify the concept that this heritable alteration in
gene expression states constitutes an alternative mechanism to
coding region mutations, or genetic alterations, for providing
loss of tumor suppressor gene function in cancer.
Despite the above, it is perhaps a good time to reflect upon
what we know and do not know about the impact of epigenetic
changes in cancer. As publication after publication accrues
reflecting the remarkable interest and research activity on the
role of epigenetic abnormalities in tumorigenesis, it is important
to realize that areas of potential confusion, and healthy skepti-
cism, exist, and must be given due attention. These revolve
around the precise functional implications for these changes in
actually driving tumor progression. Are some, or even many,
altered epigenetic states simply epiphenomena that are down-
stream from other changes that really drive tumorigenesis?
Does the promoter hypermethylation actually initiate the states
of gene silencing, or is this, again, a response pattern to a more
fundamental problem? These are some of the questions posed.
The present piece is aimed at eliciting dialog surrounding
the continued debate about the position of epigenetic abnor-
malities in the biology of cancer. Stephen Baylin, the cancer epi-
geneticist, operates from the stance of the hypothesis that epi-
genetic changes are as important as genetic ones in tumorige-
nesis and that they complement one another in fueling the
process. However, he considers viewing the areas of potential
confusion and skepticism as very constructive processes. For it
is the raising of, and careful response to, these issues that can
serve to refine the experimental approaches which are the only
way to verify or refute the hypotheses involved—and, most
importantly, which may generate the approaches and accompa-
nying data that teach us how to translate the growing body of
findings into means to better manage the diseases that contin-
ue to ravage humankind.
Timothy Bestor, the geneticist and epigeneticist, particular-
ly for studies of developmental biology, remains more skeptical
about the process, at least from a perceived lack of hard genet-
ic data to substantiate its importance and causes.
The format of this essay will be to first pose a series of
questions regarding the areas that biologists, geneticists, and
cancer researchers find confusing about reported epigenetic
alterations in cancer. In some instances, these concerns reflect
their skepticism about epigenetic changes as fundamental
steps in tumorigenesis. It is hoped that in discussing these
questions, which are substantial and important for ongoing
research, workers in the field, and those watching the field, will
benefit in the educational sense. In this vein, it is also under-
stood that the goal will not be to “answer” the questions. Rather,
in briefly reflecting upon them, sometimes debating them from
the perspective of existing data, hopefully both authors and
readers will benefit.
The first point discussed is more of a caution that has been
raised rather than a question. One danger in the field may
be a general reliance on cultured tumor cells, whose
genomic methylation patterns are known to rapidly diverge
from those found in primary tumor cells. It is methylation
abnormalities in primary material that are relevant; methyla-
tion differences found in cultured cells that are not demon-
strated to occur in primary tumors are of little interest.
Stephen Baylin: It is a perfectly correct view that one should not
attempt to judge the potential importance of promoter hyperme-
thylation for any individual gene solely through studies done in
cell culture. Rather, cell culture offers only a starting point to
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study the implications of the promoter change in terms of
degree of gene silencing, effects of induced demethylation on
gene reexpression at the mRNA and protein levels, demonstrat-
ing the effects of the gene silencing at a functional level, and
importantly, studying the mechanisms by which DNA methyla-
tion is targeted to promoter regions and how it is coupled to
transcriptional silencing. Obviously, all of this knowledge can be
useful from many different standpoints. However, for any links to
functional relevance to actual cancer progression, it is essential
to study the epigenetic status of the gene in question in primary
normal and tumor cells. In point of fact, to the author’s knowl-
edge, for every gene well characterized for epigenetically medi-
ated aberrant transcriptional silencing in cancer, and especially
for those which are classic tumor suppressor genes or which
are prime candidates for a role in tumorigenesis, promoter
hypermethylation has been well shown for primary as well as
cultured tumors (e.g., Herman et al., 1994; Dammann et al.,
2000). It should be remembered that the degree of methylation
may not always even be more extensive in the culture than in
the primary setting, but is, rather, more easily demonstrated
from a technical standpoint. The study of primary tumors, even
when microdissection techniques are utilized, is often ham-
pered by the presence of normal cells in the sample. Thus, by
any assay of methylation status used, especially the most sen-
sitive ones, unmethylated alleles of the gene under study will
always be detected. Likewise, even if the gene is completely
silenced in the primary tumor cells, some degree of expression
is almost always obtained, in assays of steady state mRNA or
protein levels, because of the presence of normal cells. One
important question for which the data are not often readily avail-
able concerns the true incidence for the hypermethylation of a
given gene in culture versus the primary setting. For many
important genes, the rates may not be that dissimilar. Recent
studies from my laboratory and that of my colleague, James
Herman, using a microarray approach to identify hypermethyla-
tion of gene promoters in colon cancer coupled to loss of gene
expression, have shown that as the candidate genes from the
screen were validated, there emerged a distinct correlation
between the incidence of hypermethylation for a given gene in a
panel of cultured colon cancers versus that found for the genes
in a substantial sized study of primary colon tumors (Suzuki et
al., 2002). It appears, then, that the methylation status in the cul-
tures may often reflect that of the tumor cells in their original
state.
Timothy Bestor: The convenience of relatively homogeneous
cell populations has led to the common use of cancer cell lines
in methylation studies. Permanent lines of cultured cells
(whether derived from tumors or normal tissues) can be methy-
lated at the majority of CpG islands associated with tissue spe-
cific genes, while these sequences remain unmethylated in all
normal somatic tissues regardless of expression status (Jones
et al., 1990; Walsh and Bestor, 1999). Maintenance in culture
imposes constant and intense selective pressures for rapid cell
division, and this leads to the loss or the silencing of genes that
restrict proliferation or that encode differentiated functions.
While analogous pressures exist within populations of progress-
ing tumor cells, the relationship of the pressures undergone by
cells in laboratory culture to those in tumors in situ is difficult to
estimate but may be quite different. Gene silencing by CpG
island methylation is certainly much more common in cultured
cells than in cells from primary tumors; Smiraglia et al. (2001)
report that head and neck squamous carcinoma cell lines show
hypermethylation at a frequency more than 90-fold greater than
the tumors of origin, while colorectal carcinoma cell lines (in
which methylation differences between cultured and primary
tumor cells were the least pronounced of any of the tumors
studied) had a 5-fold increase in focal hypermethylation over the
analogous primary tumors. More than 57% of the sequences
found to be hypermethylated in cultured tumor cells were not
methylated in any of 114 primary tumors.
It is suggested that one danger in the study of cytosine
methylation and cancer may be an undue reliance on cultured
tumor cells, whose genomic methylation patterns are known to
rapidly diverge from those found in primary tumor cells. It is
methylation abnormalities in primary material that are relevant;
methylation differences found in cultured cells that are not
demonstrated to occur in primary tumors may be of little impor-
tance to human cancer.
Can an epigenetic abnormality, like a genetic change, ever
initiate a cancer?
Stephen Baylin: This is a difficult question, not only with respect
to reviewing the evidence, but also because of the semantics
concerning when a cancer actually starts. Since transformation
is a multistep process, there are numerous preneoplastic phas-
es that human cancers evolve through that take many years.
Certainly, both losses and gains of methylation, just like genetic
changes, can accompany these early steps. Promoter hyper-
methylation is seen in key genes like p16 in preneoplastic
states, and even in some genes in normal appearing tissues as
a function of the key cancer risk state, aging (Jones and Laird,
1999). However, in all of these settings, the cells harboring such
epigenetic alterations are not absolutely fated to progress to
cancer, and if the DNA methylation changes are functional, the
consequences would have to be viewed as permissive in nature
for actual cancer and fall into the category of risk changes.
Perhaps a better stance from which to view the question is to
compare genetic and epigenetic changes for genes which
absolutely are connected with cancer by virtue of their muta-
tional status in the germline of families with distinct cancer syn-
dromes. Certain findings are intriguing. For example, VHL muta-
tions are largely restricted to renal cancers in familial and nonfa-
milial clear cell renal cancers, and so is promoter hypermethyla-
tion of this gene (Herman et al., 1994). Mutational inactivation of
the repair gene MLH1 is associated in familial and nonfamilial
cancers with the microsatelite instability phenotype, and so is
promoter methylation of this gene in nonfamilial tumors (Kane et
al., 1997; Herman et al., 1998). Recently, two groups have
reported a specific microarray pattern for BRCA1 in familial
breast cancers from patients with germline mutations in the
gene. The only nonfamilial breast tumors found to share this
microarray pattern were those with BRCA1 hypermethylation
(Hedenfalk et al., 2001; van’t Veer, et al., 2002).
While the above comparisons may be compelling for the
possibility that epigenetic alterations could technically start a
cancer, I would conclude that these situations cited do not prove
this. One key point is that mutations in a germline setting require
complementary steps to give rise to cancers, and the order of
these events for cancer formation need not be the same for the
familial versus the nonfamilial setting.Thus, the promoter hyper-
methylation in each of the above genes discussed could be a
relatively late event in the noninherited cancer types.
Technically, then, the question of cancer origin from an epige-
netic change remains an open and very difficult one to prove.
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However, the comparisons for the above genes for mutations
and promoter hypermethylation do speak strongly to the similar
selective advantages and functional consequences for loss of
function of the genes produced by their inactivation in associa-
tion with either genetic or epigenetic abnormalities.
Timothy Bestor: For this particular question, I essentially agree
with the points raised by Dr. Baylin.
There is a lack of genetic data that support the causative
role of methylation pattern abnormalities in cancer, and
especially the current absence of tumor predisposition
syndromes caused by mutations in DNA methyltransferase
genes. Such genetic data would be convincing and might
cement the true importance of the methylation changes in
cancer for their functional role.
Stephen Baylin: I heartily agree that it is extremely helpful to
consider any genetically derived data that contribute to under-
standing and documenting the importance of DNA methylation
changes in cancer, be they losses or gains. This is a legitimate
challenge to ask of promoter hypermethylation and associated
gene silencing in cancer in particular, for at least two reasons.
First, the critical role of natural genetic changes in cancer is so
well documented that it is logical to use these as a comparison
point for questioning the position of epigenetic alterations in
cancer development. Second, our ability, today, to use genetics
in experimental approaches offers perhaps the ultimate tool for
verifying or refuting the functional importance of cancer related
epigenetic changes. In other words, both the natural and exper-
imental genetics of cancer are then important vantage points
from which to view and challenge the importance of epigenetic
changes. The question of a lack of cancer predisposition syn-
dromes due to mutations, certainly of the germline type, in DNA
methyltransferases (DNMTs) is an interesting one. Predictably,
these might be activating ones from the standpoint of increasing
promoter methylation. However, cancer cells with promoter
hypermethylation of multiple genes simultaneously lose many
sites of normal methylation throughout the genome. So, this
simple prediction might not hold true. In Arabidopsis, DNMT
loss-of-function mutations actually cause both widespread loss-
es and simultaneous gains of DNA methylation at selected pro-
moters (Kishimoto et al., 2001; Lindroth et al., 2001). So, per-
haps, this scenario might occur in humans. Indeed, germline
mutations in both alleles of one of the three known biologically
active human DNMTs, DNMT 3b, do occur and give rise to the
rare ICF syndrome (Hansen et al., 1999; Okano et al., 1999; Xu
et al., 1999). Individuals with this problem, however, may not live
long enough to develop cancers. Knockout mice of all three
DNMTs are either embryonic or perinatal lethal so, on a
germline basis, mutation of any of the DNMTs might not be a
likely candidate for tumor predisposition syndromes.
Perhaps better candidates would be genes encoding chro-
matin remodeling or specifying proteins. Again, in Arabidopsis,
mutations in a remodeling protein of the Swi-Snf type cause
shifts in DNA methylation patterns similar to those above for a
DNMT (Jeddeloh et al., 1999), and knockout of an ortholog for
this protein in mice has recently been reported to cause loss of
DNA methylation in embryos (Dennis et al., 2001). Finally, loss
of function mutations in histone methyltransferases, in
Neurospora (Tamaru and Selker, 2001) and Arabidopsis
(Jackson et al., 2002), which specifically methylate at lysine 9
residues of histone H3, setting up a posttranslational change
critical for establishing transcriptionally repressive chromatin
(Jenuwein and Allis, 2001), cause losses of DNA methylation.
So, it seems that looking for either germline or somatic muta-
tions in the DNA methylation “machinery” proteins that may be
linked to cancer predilection and/or somatic tumorigenesis is
certainly a valid consideration. Likely, work is ongoing within this
arena.
Even in the absence of association between cancer and the
above types of natural mutations, I would maintain, however,
that there are in fact several key genetic data points, some of
which are provided by nature and others which have recently
been experimentally derived, that point to the importance of
promoter hypermethylation changes and/or the associated
gene silencing. More will be useful, but to date, the following
seem compelling. First, the data of Laird et al. (1995) that the
knockout of the DNA methyltransferase-1 (Dnmt1) gene leads
to loss of gastrointestinal tumorigenecity in mice lacking the
APC gene is intriguing.The leading candidate mechanisms cur-
rently proposed by the lead author of the above original study is
the elimination of promoter methylation and silencing of tumor
suppressor genes (Eads et al., 2002). Some evidence for this is
accruing (Eads et al., 2002), but this issue remains to be fully
resolved.
Second, the question of selective advantage for epigenetic
changes should always be carefully examined, and when juxta-
posed to genetic changes, there is now very compelling data for
the functional role of promoter methylation in tumorigenesis. In
a long-established colorectal cell line, HCT 116, it is well docu-
mented that one mutant allele of p16 is mutated and nonfunc-
tional, but expressed, while the opposite allele is hypermethylat-
ed and fully silenced (Myohanen et al., 1998). While this exam-
ple suffers from being restricted to cell culture, an issue that is
addressed above, similar scenarios have emerged in native
tumor situations. Thus, studies of E-cadherin hypermethylation
in families with germline mutations in this gene, a situation in
which members get gastric cancers, reveal that the methylation
change in the tumors always acts as a “second hit” by being pre-
sent, in tumors retaining both E-cadherin alleles, on the nonmu-
tated allele (Grady et al., 2000). Likewise, in a more recent and
large study of several inherited cancer types, arising in the set-
ting of germline mutations, hypermethylation of the involved
gene in tumors from individuals within the kindreds was never
seen in those in which the opposite allele of the germline mutat-
ed gene was lost, but was not uncommon in tumors where both
alleles were retained (Esteller et al., 2001).
Third, recent evidence juxtaposing a natural genetic event
with experimental data in acute promyelocytic leukemia cells
gives rise to the consideration of a line of research which could
heartily solidify the functional role of promoter hypermethylation
and gene silencing in cancer. Thus, translocation of the tran-
scription factor gene, RARα, to create a fusion protein with
PML, appears to correlate with hypermethylation of the promot-
er and gene silencing of a candidate downstream transcription-
al target of RARα, RARβ. Moreover, the induction of binding of
multiple DNMTs to the target promoter accompanies this sce-
nario, as does an altered nuclear localization of these proteins
(Di Croce et al., 2002). These events are not seen when RARα
acts as a transcriptional activator of the downstream gene
rather than a repressor, as it does when in the context of the
fusion protein. It must be cautioned that it is not certain that the
target gene promoter for RARα is a natural one for RARβ, and
much work remains to ferret out the true significance of these
above findings.
302 CANCER CELL : MAY 2002
F O R U M
Finally, a very recent collaborative study, involving experi-
mental genetic manipulation of cancer cells, strongly suggests
the role of the promoter hypermethylation in epigenetically
silencing of genes in cancer and the consequences of this
mode of gene inactivation for the tumor phenotype. When both
the DNA methyltransferase 1 and 3b genes are fully disrupted in
HCT 116 colon cancer cells, virtually all DNA methylation is lost
from the cells, and the hypermethylation in tumor suppressor
genes, including the wild-type copy of p16 and an imprinted
gene, is relieved with associated gene reexpression (Rhee et
al., 2002). Furthermore, a single cell clone in this study where
the p16 gene did not demethylate, but the other studied genes
did, grows dramatically faster than all of the other double knock-
out clones which, in turn, grow much slower than the wild-type
clones. The product of this gene is a powerful brake for cell
growth, and the continued suppressed expression of the wild-
type allele may well explain the behavior of this clone.
In summary, there appears to be a growing body of genetic
data to support the functional significance of DNA methylation
changes in cancer. More data are needed which either comple-
ment, refute, or alter the interpretations that have been offered
above.
Timothy Bestor: The cause-versus-consequence problem has
long been a serious problem in the cytosine methylation field,
which has traditionally placed undue reliance on correlative evi-
dence.The finding of a methylated and silent promoter does not
require that the methylation be the cause of the silencing; long-
term inactivity for other reasons may predispose a gene to de
novo methylation. The binding of transcription factors such as
Sp1 can cause demethylation of local CpG sites in cycling cells,
and even E. coli lac repressor bound to lac operator sequences
in mammalian cells can induce demethylation of nearby CpG
sites (Lin et al., 2000, and references therein). De novo methy-
lation observed at specific genomic foci may reflect not a prima-
ry epigenetic silencing event but rather the consequences of
loss of expression due to upstream mutational events in signal
transduction cascades or transcription factor networks. The
association of de novo methylation with a specific gene cannot
be taken as evidence that the gene was silenced by methyla-
tion; the methylation may have little to do with the primary extin-
guishing event.
There is at present a lack of genetic data to support the
causative role of methylation pattern abnormalities in cancer.
While the products of many oncogenes and tumor suppressor
genes are involved in signal transduction, control of transcrip-
tion, DNA repair, cell cycle control, cell-cell interactions, and
other processes, none have been shown to be directly involved
in the establishment or maintenance of genomic methylation
patterns or the specific binding of methylated sites. Somatic
mutations in DNA methyltransferase genes have not been
reported for any tumor, and the lack of tumor predisposition syn-
dromes caused by mutations in DNA methyltransferase genes
is also notable. Were such genetic evidence available, there
would be a compelling case for a causative role of methylation
abnormalities in cancer. While it has been reported that het-
erozygosity for mutations in Dnmt1 in mice modifies the pene-
trance of the APC/Min mutant mice by reducing the number of
benign polyps in colonic epithelia (Eads et al., 2002), it has not
been shown that the methylation status of any sequence related
to cancer is detectably altered in such animals, nor has het-
erozygosity at Dnmt1 been shown to modify the penetrance of
mutations that predispose to malignant tumors. In one of the few
other cases where genetic data linked methylation and malig-
nant disease, the Dnmt1 gene was shown to be amplified in
Friend murine erytholeukemia cells (Bestor et al., 1988).
However, this is very likely to be due to coamplification of Dnmt1
with the erythropoietin receptor (Epor) gene, which is located
very close to Dnmt1 on proximal mouse chromosome 9 and
which is involved in leukemic transformation via activation of
Epor by retroviral envelope glycoprotein gp55 (reviewed by
Ruscetti, 1999). Amplification of Dnmt1 in this case was most
likely due to proximity to the target gene, and no direct evidence
for a role of Dnmt1 in carcinogenesis has appeared.
Overexpression of Dnmt1 in tumors is small in extent, if it occurs
at all (Eads et al., 1999; Lee et al., 1996; Schmutte et al., 1996).
Confirmation of cases in which a primary defect in a methyla-
tion-related gene can be demonstrated to be essential for
tumorigenesis would remove much of the existing uncertainty
as to the importance of cytosine methylation in the etiology of
cancer.
At present, there is a lack of a plausible mechanism that
might lead to the de novo methylation of CpG islands in
somatic cells. Is promoter methylation the cause of silenc-
ing, or is it the consequence of a loss of expression due to
mutations in genes that encode regulatory factors? In
some tumor types (colorectal and urogenital) there is a
global reduction in methylation levels with evidence of
focal increases. A testable hypothesis that could explain
this situation is urgently needed.
Stephen Baylin: I agree that the above are absolutely, and per-
haps the most, fundamental questions in the field. Among them
are some that have long confounded understanding of the role
of methylation in transcriptional control, not only in cancer cells,
but in mammalian cells in general. The ones concerning tran-
scription embody the chicken and egg question of whether the
DNA modification is the cause of silencing, or the consequence.
This does not negate the importance of the promoter hyperme-
thylation associated with aberrant gene silencing in cancer if the
process it is associated with is involved with gene inactivation
that is important for the tumor phenotype. However, for all work-
ing in the field, the questions are pivotal and emblematic of the
type of constructive skepticism and debate that should be cen-
tral to designing experimentation which could hold the key to full
understanding of the processes under discussion.
Could it be possible that the answer to the above questions
may well encompass an unexpected paradigm? Recent data
suggest that all of the active mammalian DNA methyltransferas-
es (DNMTs) may be capable of directly silencing transcription
separately from catalyzing methylation (Fuks et al., 2000, 2001;
Robertson et al., 2000; Rountree et al., 2000; Bachman et al.,
2001). Might it then be possible that gene silencing and methy-
lation are so integrally coupled that this has confounded
attempts to order them temporally by direct experimental
approaches? In other words, the interaction of the DNMTs with
any promoter might always help initiate silencing and some-
times couple this with methylation. In the truest sense, then, the
silencing might come first, but barely. This hypothesis, even if it
holds true, would not negate the possibility that mutations in
regulatory factors could underlie the abnormal methylation pat-
terns, including those in promoters associated with gene silenc-
ing, in cancer. The proteins involved might be those that help
target DNMTs properly to chromatin or associate with them
once they do. If so, such mutations could explain, at once, the
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fact that cancer cells have global loss of methylation and region-
al gains, if failure to target some sites might allow access to
aberrant ones. Again, the studies cited previously in
Arabidopsis outlining mutations in DNMTs themselves and in
chromatin remodeling proteins, which lead to losses and gains
of DNA methylation, well illustrate the potential for this scenario.
Such a finding in human tumors would not, in and of itself,
answer the chicken and egg question. However, it would be
incredibly exciting and would help complete a circle in which,
during tumor progression, genetic changes could induce epige-
netic ones, which can in turn, as for silencing of the hMLH1
gene (Kane et al., 1997; Herman et al., 1998), produce further
genetic changes.
In terms of the types of mutations that could reset the can-
cer genome for chromatin patterns, one must now consider
heavily the recent exciting data concerning the role of the his-
tone code in establishing chromatin patterns. Certainly, methy-
lation of lysine 4 and 9 of histone H3 tails is intimately associat-
ed with transcriptionally active versus repressive chromatin,
respectively (Jenuwein and Allis, 2001). Further, as previously
noted, data in Neurospora and Arabidopsis have emerged firm-
ly indicating that mutations in enzymes mediating the lysine 9
methylation, histone methyltransferases (HMTs), lead to altered
DNA methylation.While the alterations reported, to date, involve
losses of the DNA modification, might it not be reasonable to
suspect that gains might also ensue if specific lysine 4 or 9
HMTs, or proteins with which they associate, are altered? The
tools appear to be at hand to frame reasonable hypotheses con-
cerning the concomitant losses and gains of DNA methylation in
cancer cells and to use these to provide a molecular basis for a
key aspect of the neoplastic phenotype.
Timothy Bestor: De novo methylation of CpG islands could rep-
resent a simple epimutation in which accidental methylation of
CpG sites in islands that are normally unmethylated causes the
heritable transcriptional silencing of the associated gene. This
could contribute to tumor progression if the silencing event
endows the cell with a growth advantage in the tumor cell popu-
lation. In this model, the affected gene presents no features that
predispose it to methylation, and de novo methylation is essen-
tially a stochastic event. Given the nearly complete lack of
understanding of the cues that designate single copy
sequences for de novo methylation at any stage of develop-
ment, the random model remains valid. However, experiments
on methylation and silencing of the hMLH1 gene suggest that
additional factors are involved.
A subset of colorectal carcinoma cell lines showed
microsatellite instability and did not express the hMLH1 DNA
repair gene, although the sequence of both hMLH1 alleles was
normal (Veigl et al., 1998). The 5′ CpG islands of both alleles
were found to be methylated, and hMLH1 expression could be
induced by culture in the presence of 5-aza 2’-deoxycytidine
(azaC), a specific inhibitor of DNA cytosine methyltransferases.
However, withdrawal of azaC was followed by silencing and
remethylation of both alleles, and reexposure to azaC again
caused transient expression of hMLH1 transcripts. The rapid
and concerted remethylation of hMLH1 upon removal of the
methylation inhibitor in these experiments is difficult to reconcile
with the random de novo methylation model, which predicts a
slow and stochastic process. The demethylation induced by
azaC was sufficient to allow full access of transcription factors,
as shown by the activity of the promoter after demethylation.
The locus either underwent alterations of sequence or of herita-
ble chromatin configurations that predisposed them to silenc-
ing, or the initial silencing event was wholly stochastic and some
unidentified remnant of the silent state was sufficient to over-
come the reactivated promoter and cause resilencing upon
withdrawal of demethylating agent. It should also be noted that
in this case transcriptional activity was insufficient to protect the
promoter region from de novo methylation; as noted below, the
binding of factors such as Sp1 to cellular sequences or even lac
repressor to lac operator transgenes can cause demethylation
of local sequences. The hMLH1 silencing studies are not com-
patible with the simple stochastic de novo methylation hypothe-
sis, and fundamental questions about the mechanism of methy-
lation and gene silencing in cancer are raised by these studies.
What does the hypomethylation side of the coin contribute
to tumorigenesis?
Stephen Baylin: Certainly, there is an excellent body of literature
documenting both global and gene specific loss of methylation
in cancer (e.g., Feinberg and Vogelstein, 1983; Feinberg et al.,
1988). It remains, however, to be proven exactly what the con-
sequences of this change are with respect to specific events in
tumorigenesis. The work previously discussed concerning
mutations of DNMT3b underlying the ICF syndrome amply sug-
gests the potential role of methylation loss for chromosomal
instability, and that has been a major hypothesis for the conse-
quences of genomic hypomethylation in cancer. Another
hypothesis, as I’m sure Dr. Bestor will address, is the possibility
for unwanted transcription of repeated elements from areas of
methylation loss in cancer cells. This area of epiegentic change
in cancer is certainly of continued potential importance and war-
rants continued clever experimentation to demonstrate its exact
significance(s) for tumorigenesis.
Timothy Bestor: Most solid tumors present with aneuploid and
severely rearranged karyotypes, and some (notably colorectal
and urogenital carcinomas; reviewed by Schulz, 1998) are also
characterized by global genome hypomethylation. While many
sources of genome destabilization have been identified, the role
of methylation patterns in genome stability has received little
attention. The large majority of cytosine methylation lies within
repeated sequences (Yoder et al., 1997), primarily the trans-
posons that make up more than 45% of the human genome;
demethylation would be expected to unmask repeats and
increase the frequency of rearrangements caused by homolo-
gous recombination between nonallelic repeats. Results of
experiments in embryonic stem cells homozygous for mutations
in Dnmt1 support this conclusion; mutation rates at introduced
marker loci were elevated 5- to 10-fold in demethylated
genomes, and the mutations were primarily rearrangements
rather than point mutations (Chen et al., 1998). The global
demethylation characteristic of certain tumor types may predis-
pose to genome instability via homologous recombination
between unmasked repeats rather than favoring dysregulation
of gene expression, as was originally envisioned.
Conclusions
Stephen Baylin: It is hoped that, in the above discussions, I
have kept to the promise of not “answering” questions that have
not yet been answered. Obviously, human nature dictates that
some personal biases will come through. Those of us in cancer
research who would be, or are, called “epigeneticists” are, per-
haps, seduced into thinking we have come a long way consider-
ing the virtual explosion in interest for this field over the last few
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years. Perhaps we are still just starting and only continued well-
focused research will provide data that will be the substrate for
history to put the story, especially for cancer, in its proper per-
spective. In so doing, things may appear quite different in the
future from the view we have today.
Timothy Bestor: Are disturbances of genomic methylation pat-
terns directly involved in carcinogenesis, and if so, what fraction
of tumor incidence involves such abnormalities? These ques-
tions are very difficult to answer at this time, due in large part to
the lack of plausible and testable candidate mechanisms that
could lead the cell to participate in the irreversible silencing of
genes that are required for normal cellular function. Progress
will depend on a better understanding of the factors that silence
expression of genes that are in the presence of the full comple-
ment of factors normally required for their expression.
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